Price (delayed)
$1.94
Market cap
$2.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$10.2
Enterprise value
$2.83M
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are
There are no recent dividends present for VIVS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.